Date of submission of the HTAC Recommendation: 18 March 2026Date of notification to HTAC on the SOH decision: 07 May 2026 The Secretary of Health (SOH) concurs with the final recommendation of the HTA Council on Epidermal Growth Factor Receptor (EGFR) Polymerase Chain Reaction (PCR) Mutation Test for the diagnosis of EGFR mutations in patients continue reading : HTA Council Final Recommendation on Epidermal Growth Factor Receptor (EGFR) Polymerase Chain Reaction (PCR) mutation test for the diagnosis of EGFR Mutations in patients with Non-Small Cell Lung Cancer (NSCLC) (with Secretary of Health Decision)
HTA Council Final Recommendation on erlotinib (25 mg, 100 mg, and 150 mg film-coated tablet), gefitinib (250 mg tablet and film-coated tablet), and afatinib (20 mg, 30 mg, and 40 mg film-coated tablet) for the treatment of Epidermal Growth Factor Receptor (EGFR) mutation – postitive Non-Small Cell Lung Cancer (NSCLC) (with Secretary of Health Decision)
Date of submission of the HTAC Recommendation: 12 March 2026Date of notification to HTAC on the SOH decision: 07 May 2026 The Secretary of Health (SOH) concurs with the final recommendation of the HTA Council on Erlotinib (25 mg, 100 mg, and 150 mg film-coated tablet), Gefitinib (250 mg tablet and film-coated tablet), and Afatinib continue reading : HTA Council Final Recommendation on erlotinib (25 mg, 100 mg, and 150 mg film-coated tablet), gefitinib (250 mg tablet and film-coated tablet), and afatinib (20 mg, 30 mg, and 40 mg film-coated tablet) for the treatment of Epidermal Growth Factor Receptor (EGFR) mutation – postitive Non-Small Cell Lung Cancer (NSCLC) (with Secretary of Health Decision)
HTA Council Final Recommendation on Reteplase (10 units lyophilized powder for IV injection) for ST-Elevation Myocardial Infarction Patients
The Secretary of Health (SOH) acknowledges the final recommendation of the HTA Council on reteplase (10 units lyophilized powder for IV injection) for ST-Elevation Myocardial Infarction (STEMI) patients (date of receipt of acknowledgment: 02 January 2025). As a final recommendation, the HTA Council does not recommend the government financing of reteplase for STEMI patients. For continue reading : HTA Council Final Recommendation on Reteplase (10 units lyophilized powder for IV injection) for ST-Elevation Myocardial Infarction Patients
HTA Council Final Recommendation on Cerebrolysin [215.2 mg/ml, 10ml ampule for IV infusion] for the Treatment of adults with Post-Ischemic Stroke
The OIC-Secretary of Health (SOH) notes the final recommendation of the HTA Council on Cerebrolysin 215.2 mg/ml, 10ml ampule for IV infusion in combination with rehabilitation or standard of care for the treatment of adults with post-ischemic stroke (date of receipt of acknowledgment: 25 April 2023). As a final recommendation, the HTA Council does not continue reading : HTA Council Final Recommendation on Cerebrolysin [215.2 mg/ml, 10ml ampule for IV infusion] for the Treatment of adults with Post-Ischemic Stroke
HTA Council Final Recommendation on Ceftaroline fosamil (600 mg powder for concentrate for solution for injection) for the treatment of community-acquired pneumonia (CAP) in the pediatric population
The Secretary of Health (SOH) acknowledges the final recommendation of the HTA Council on ceftaroline fosamil (600 mg powder for concentrate for solution for injection) for the treatment of community-acquired pneumonia (CAP) in the pediatric population (date of receipt of acknowledgment: 13 January 2026). As a final recommendation, the HTA Council does not recommend the continue reading : HTA Council Final Recommendation on Ceftaroline fosamil (600 mg powder for concentrate for solution for injection) for the treatment of community-acquired pneumonia (CAP) in the pediatric population